Google
Trusted Resources: News & Events
Latest announcements and gatherings
Investigational Therapy Altemia Achieves Main Endpoints in Pediatric Sickle Cell Trial
Sancilio Pharmaceuticals says its investigational therapy Altemia (SC411) achieved primary and secondary endpoints in a clinical trial with sickle cell patients 5 to 17 years old. Altemia is a combination of specific lipids designed to restore balance to the membrane of red blood cells that are damaged in sickle cell disease patients. The therapy uses Sancilio’s proprietary Advanced Lipid Technologies (ALT) platform.
The Phase 2 trial (NCT02973360) primary endpoint was the change from baseline in the concentration of fatty acids in the red blood cell membrane of patients treated with one of the three active doses of Altemia, or matching placebo. Fatty acids are a major component of cellular membrane.
+myBinderRelated Content
-
Treatment Advances in Sickle Cell Disease, Amber M. Yates, MDhttps://www.youtube.com/watch?v=oFIOKC4r...
-
ADDMEDICA receives FDA-approval for orphan drug Siklos®, first and sole hydroxyurea-based treatment for paediatric ...ADDMEDICA has announced that the...
-
Hydroxyurea linked to ‘significant, rapid’ reduction of sperm countSix months of hydroxyurea therapy detrim...
-
Developmental Profile of Sleep and Its Potential Impact on Daytime Functioning From Childhood to Adulthood in Sickle...Young individuals with sickle cell anaem...
-
Moderate-intensity endurance-exercise training in patients with sickle-cell disease without severe chronic complicat...Background: Exercise could be a trigger...
-
Sickle Cell Disease: After Years of Neglect Some Promise for SufferersIt’s Black History Month, when the nat...
-
ASH Clinical Practice Guidelines on Sickle Cell Disease (SCD)https://www.youtube.com/watch?v=tozUcTSN...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.